Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Open this folder and view contentsIV. Preliminary findings
Open this folder and view contentsV. Conclusions of the workshop and follow-up plans
Open this folder and view contentsAnnex 1: Research proposal
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Open this folder and view contentsAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series

Other documents in the DAP Research Series

N°. 1 Injection practices research

N°. 2 How to investigate drug use in communities (also available in French)

N°. 3 Operational research on the rational use of drugs

N°. 4 Development of indicators for monitoring national drug policies

N°. 5 People's perception and use of drugs in Zimbabwe

N°. 6 Operational research in the Action Programme on Essential Drugs: Report of an informal consultation

N°. 7 How to investigate drug use in health facilities: Selected drug use indicators (also available in French and Spanish)

N°. 8 Stability of injectable oxytocics in tropical climates: Results of field surveys and simulation studies on ergometrine, methylergometrine and oxytocin

N°. 9 Prescription des antibiotiques dans trois pays d'Afrique de l'Ouest: Mauritanie, Niger et Sénégal

N°. 10 Self-medication and its impacts on essential drugs schemes in Nepal

N°. 11 Injection practices: A case study in Thailand

N°. 12 Stability of oral oxytocics in tropical climates

N°. 13 Stability of essential drugs in tropical climates: Zimbabwe

N°. 14 Injection practices: A case study of Uganda

N°. 15 Community health workers and drugs: A case study of Thailand

N°. 16 Use of the WHO Certification Scheme on the Quality of Pharmaceutical
Products Moving in International Commerce

N°. 17 Impact of a short course in pharmacotherapy for undergraduate medical students: An international multicentre study

N°. 18 La qualité des médicaments sur le marché pharmaceutique africain
Etude analytique dans trois pays: Cameroun, Madagascar, Tchad

N°. 19 Operational research projects in the Action Programme on Essential Drugs: An annotated inventory

N°. 20 Injection practices in the developing world
A comparative review of field studies in Uganda and Indonesia

N°. 21 Le secteur pharmaceutique privé commercial au Maroc:
Dynamique de développement et effets sur l'accessibilité des médicaments

N°. 22 La libéralisation du secteur pharmaceutique en Algérie:
Effets sur la disponibilité et les prix des médicaments

N°. 23 Le secteur pharmaceutique privé commercial au Sénégal: Dynamique de développement et effets sur l'accès aux médicaments essentiels

N°. 24 Public education in rational drug use: A global survey

DAP Research Series No. 25

The WHO Action Programme on Essential Drugs seeks to ensure that all people, wherever they may be, are able to obtain the drugs they need at a price that they and their country can afford; that these drugs are safe, effective and of good quality; and that they are prescribed and used rationally. It provides operational support to countries in the development and implementation of national drug policies based on the concept of essential drugs and it promotes the rational use of drugs at every level.

Ensuring access to and rational use of drugs for all people is a difficult goal in itself. It is made even more complicated to achieve by rapidly changing macro-economic and national environments. Countries are experiencing the effects of international adjustment and stabilization policies; globalization of world markets; new disease patterns; widespread health system reforms with shifting priorities, and a changing relationship between the public and private sectors. Governments lack crucial information to guide their national drug policies in response to these challenges.

Operational research makes a vital contribution to identifying global and national drug sector problems and priority areas for intervention. At global level, the systematic development and analysis of internationally comparable data on pharmaceutical systems strengthen national drug policy by enabling countries to learn from each other's experience. At national level, research assists countries in analysing the constraints they face in developing and implementing drug policies and in gaining knowledge about the best means of selecting, procuring and distributing drugs, as well as the use of drugs by prescribers and consumers. The results of such operational research have a direct bearing on strategies to make vital medicines available and accessible to the greatest number of people.

This document is part of a series reporting on the activities and results of the Action Programme's operational research.

to previous section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017